Showing results (341-350 of 396) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2Niamh Coleman, Zihan Wei, A John Iafrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public WorkshopKristen L Mueller, Marc R Theoret, Steven J Lemery, et al.
The British Journal of Dermatology|March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational studyXue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
JCI Insight|February 23, 2018
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumorsStergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
EMBO Molecular Medicine|April 14, 2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanomaIleabett M Echevarría-Vargas, Patricia I Reyes-Uribe, Adam N Guterres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
JCO Precision Oncology|August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.
Pageof 40